Evidence-based due – an integrative benefit-risk decision making on proton pump inhibitors

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-054
• By: HSIEH, Hui-Hsia (Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Pharmacy, Taichung, China Taiwan)
• Co-author(s): Hui-Hsia Hsieh:
  Tien-Yuan Wu: Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China;Pharmacology, Tzu Chi University, Hualien, Taiwan, Province of China
  Hsun-Yang Chuang: Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China
  Chi-Hua Chen: Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China
  Mann-Jen Hour: Pharmacy, China Medical University, Taichung, Taiwan, Province of China
  
• Abstract:

  Background

  The American College of Gastroenterology recommendations that high-dose continuous infusion of proton pump inhibitors (PPIs) should be given to the high-risk bleeding ulcer patients after endoscopic management. The other meta-analysis studies showed that non-high dose intermittent PPI therapy is not inferior to high-dose continuous..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login